Wave (WVE) Reports Q1 2025 Earnings with Revenue Decline and Increased Expenses
Wave (WVE) reported Q1 2025 earnings with revenue of $9.2 million, down from $12.5 million in the prior year, due to timing of collaboration revenue. The company also saw increased R&D and G&A expenses, leading to a net loss of $46.9 million. Despite the financial challenges, the WVE-N531 DMD program showed positive results with statistically significant improvements in dystrophin expression.
Topics: Cash Reserves DMD Program FDA Interactions G&A Expenses Net Loss R&D Expenses Revenue